- Conditions
- Healthy Volunteers
- Interventions
- Midazolam, Cefiderocol
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–88
of 88
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obsessive Compulsive Disorder
- Interventions
- Ketamine, Midazolam
- Drug
- Lead sponsor
- Wayne Goodman MD
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Congenital Heart Disease
- Interventions
- continuous infusion, as needed dosing, Acetaminophen, ketorolac
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 3 Months to 4 Months
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Oak Lawn, Illinois
- Conditions
- Major Depressive Disorder
- Interventions
- Ketamine infusion, Midazolam infusion
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Major Depressive Disorder, Anxiety Disorder
- Interventions
- Ketamine, Midazolam
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut
- Conditions
- Posttraumatic Headache, Posttraumatic Stress Disorder
- Interventions
- Group A active comparator, Group B active comparator, Group C Experimental, Group D Placebo Comparator
- Procedure · Drug · Combination Product + 1 more
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Bethesda, Maryland • Fort Bragg, North Carolina
- Conditions
- Sedation
- Interventions
- Midazolam, Fentanyl/Morphine, Dexmedetomidine
- Drug
- Lead sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 28 Weeks to 44 Weeks
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 17
- States / cities
- Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 14 more
- Conditions
- Fatigue
- Interventions
- Ketamine, Midazolam
- Drug
- Lead sponsor
- National Institute of Nursing Research (NINR)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Prostate Cancer, Urothelial Carcinoma, Neuroendocrine Tumor (NET), Neuroendocrine Carcinoma (NEC), Soft Tissue Sarcoma, Nuclear Protein in Testis (NUT) Carcinoma
- Interventions
- MT-4561
- Drug
- Lead sponsor
- Tanabe Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Grand Rapids, Michigan • Columbus, Ohio + 1 more
- Conditions
- Hospital Inpatient Trauma Injury, Pain Management
- Interventions
- Ketamine, Placebo
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Acute Respiratory Failure
- Interventions
- Sedation Protocol with Daily Interruption, Sedation Protocol Without Daily Interruption, Fentanyl Push First
- Drug
- Lead sponsor
- MemorialCare Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Long Beach, California
- Conditions
- Scorpion Sting Envenomation
- Interventions
- Antivenin Centruroides (scorpion) equine immune F(ab)2, Placebo
- Biological · Other
- Lead sponsor
- Instituto Bioclon S.A. de C.V.
- Industry
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 2
- States / cities
- Tucson, Arizona
- Conditions
- Laparoscopic Colorectal Resection
- Interventions
- TAP block, Epidural, Paravertebral block, Acetaminophen 1g IV, Dexamethasone 4mg, Midazolam up to 2mg, Propofol 1-2.5 mg/kg, Sevoflurane to keep a bispectral index of between 40-60, Local infiltration with 10 mL of plain ropivacaine 0.25%, Lidocaine, Epinephrine, Hydromorphone
- Procedure · Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Treatment Resistant Depressive Disorder
- Interventions
- Ketamine, Midazolam
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 55 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Tobacco Smoking
- Interventions
- Ketamine, Midazolam, Dexmedetomidine, Saline
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
- Interventions
- Ketamine, Midazolam
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas